ADV Pharma is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €2.51M and a net result of €556k. Equity is growing by ~13.1% per year across the filed fiscal years. Its solvency ranks better than 35% of 5498 sector peers (fiscal year 2025). The company has been active since 2011 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Outside the general model
Model not applicable to financial institutions
The health score weighs liquidity, leverage and margins against norms for trading and manufacturing companies. A bank, insurer or financial holding has a fundamentally different balance-sheet structure, so those ratios, and hence the score, carry no meaning here. That is why we show no financial axes either.
Credit advice for your own amount and term
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
28 d early
2024
17 d early
2023
1 d early
2022
17 d early
2021
4 d early
2020
6 d late
2019
8 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
17-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€2.51M▼ 6.8%
2024 · €2.69M
2018: €1.16M
2019: €1.22M
2020: €1.63M
2021: €2.01M
2022: €2.14M
2023: €2.26M
2024: €2.69M
2018 → 2025
Net result
€556k▼ 23.7%
2024 · €730k
2018: €597k
2019: €330k
2020: €978k
2021: €688k
2022: €524k
2023: €723k
2024: €730k
2018 → 2025
Total assets
€7.25M▲ 25.7%
2024 · €5.77M
2018: €3.61M
2019: €3.63M
2020: €4.30M
2021: €5.09M
2022: €5.79M
2023: €6.01M
2024: €5.77M
2018 → 2025
Solvency
34.6%▼ 12.1pp
2024 · 46.6%
2018: 32.0%
2019: 33.7%
2020: 37.8%
2021: 39.6%
2022: 36.9%
2023: 37.7%
2024: 46.6%
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€2.01M-€2.14M▲ 6.2%€2.26M▲ 5.8%€2.69M▲ 19.0%€2.51M▼ 6.8%
Operating result€277k-€214k▼ 22.7%€384k▲ 79.5%€472k▲ 23.0%€331k▼ 29.8%
Net result€688k-€524k▼ 23.7%€723k▲ 37.8%€730k▲ 1.0%€556k▼ 23.7%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 30% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €7.25M
Fixed assets
€5.26M▲ 49.8%
Current assets
€1.99M▼ 11.8%
Equity and liabilities €7.25M
Equity
€2.51M▼ 6.8%
Debt
€4.74M▲ 54.1%
The debt ratio rises from 53.4% to 65.4%. Equity is lower and debt is higher.
Key figures and ratios
Solvency
34.6%▼
2024 · 46.6%
ROE
22.2%▼
2024 · 27.1%
ROA
7.7%▼
2024 · 12.6%
Debt
€4.74M▲
2024 · €3.08M
Debt ≤ 1 year
€2.83M▲
2024 · €2.01M
Debt > 1 year
€1.92M▲
2024 · €1.07M
Income taxes
€30k▼
2024 · €106k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€5.77M€7.25M▲
Fixed assets21/28€3.51M€5.26M▲
Tangible fixed assets22/27€769k€2.52M▲
Land and buildings22€715k€1.18M▲
Plant, machinery and equipment23€760€311▼
Furniture and vehicles24€834€244▼
Assets under construction and advance payments27€52k€1.34M▲
Financial fixed assets28€2.74M€2.74M=
Current assets29/58€2.26M€1.99M▼
Amounts receivable within one year40/41€1.27M€1.19M▼
Trade receivables40€7k-
Other amounts receivable41€1.26M€1.19M▼
Cash at bank and in hand54/58€371k€126k▼
Deferred charges and accrued income490/1€620k€675k▲
Equity and liabilities
Total equity and liabilities10/49€5.77M€7.25M▲
Equity10/15€2.69M€2.51M▼
Contributions10/11€100k€100k=
Reserves13€1.95M€1.71M▼
Non-distributable reserves130/1€10k€10k=
Reserves not available under the articles1311€10k€10k=
Distributable reserves133€1.94M€1.70M▼
Profit (loss) carried forward14€644k€700k▲
Amounts payable17/49€3.08M€4.74M▲
Amounts payable after more than one year17€1.07M€1.92M▲
Financial debts170/4€998k€1.84M▲
Other amounts payable178/9€75k€72k▼
Amounts payable within one year42/48€2.01M€2.83M▲
Current portion of amounts payable after more than one year42€281k€282k▲
Financial debts43-€75k
Credit institutions430/8-€75k
Trade debts44€72k€450k▲
Suppliers440/4€72k€450k▲
Taxes, remuneration and social security45€155k€69k▼
Taxes450/3€155k€69k▼
Other amounts payable47/48€1.50M€1.95M▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€26k€26k▼
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€69k
Other operating charges640/8€0-
Gross operating margin9900€498k€426k▼
Operating profit (loss)9901€472k€331k▼
Financial income75/76B€407k€301k▼
Recurring financial income75€407k€301k▼
Financial charges65/66B€43k€46k▲
Recurring financial charges65€43k€46k▲
Profit (loss) for the period before taxes9903€836k€586k▼
Income taxes67/77€106k€30k▼
Profit (loss) for the period9904€730k€556k▼
Profit (loss) for the period to be appropriated9905€730k€556k▼
Appropriation of the result
Profit (loss) to be appropriated9906€1.67M€1.20M▼
Profit (loss) brought forward from the previous period14P€939k€644k▼
Transfer from equity791/2-€540k
Transfer to equity691/2€725k€300k▼
To other reserves6921€725k€300k▼
Profit to be distributed694/7€300k€740k▲
Return on contributions (dividend)694-€540k
Directors or managers695€300k€200k▼
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
03-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
14-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
30-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
14-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
27-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Equity above €2MEq €2.01M ▲23.8%
4 profitable years in a row build equity to €2.01M.
06-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 6 days late
2020
31-12
Financial
Highest result since 2018net €978k ▲197%
Operating result €499k, net result €978k, both a record.
23-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
31-12
Financial
Weakest financial yearnet €330k ▼44.8%
Net result drops to €330k, the lowest in the series; recovery starts the following year.
19-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 19 days late
2018
31-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
13-09
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 44 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Rebecq · 1 establishment unit since 2011
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Route de Quenast 151430 RebecqGround area
3,115 m²
Building footprint
437 m²
Volume, LiDAR
3,560 m³
2 parcels, Wallonia · tallest building 13.6 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
ADV Pharma
since 20112.196.610.035
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52055C0138/00Z004 | Wallonia | 1,936 m² | 1 · 204 m² | 8.3 m · 2 fl. |
| 25007B0204/00P003 | Wallonia | 1,178 m² | 1 · 233 m² | 13.6 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHALCO
BE 0473.481.447
Celles (lez-Tournai) · Eq €2.51M
FREVAN
BE 0457.574.932
Asse · Eq €2.51M
STEFKO INVEST
BE 0553.719.154
Berlare · Eq €2.51M
RES
BE 0427.706.751
Tienen · Eq €2.50M
Maconne
BE 0775.616.354
Antwerpen · Eq €2.50M
Of 24,726 companies in sector 64210 we hold annual accounts for 19,747. 10,245 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded14-02-2011
Fiscal year end31-12
Activities, NACEBEL
64200Holdings
64210Activities of holding companies
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 15 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.